ClinicalTrials.gg
CompletedNCT06186492RestorAATion-1Updated Mar 23, 2026Results posted

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

A Phase 1 interventional study of WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD), sponsored by Wave Life Sciences USA, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Wave Life Sciences USA, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.

Enrollment
16th of 25
47 · median 54
Started
2023
with 4 others
Phase 1
7 of 28
1 open now
Registered
20th of 28
by date
Lead sponsor
2 of 28
Wave Life Sciences USA, Inc.

Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 1, and was the 20th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is the first study in the RestorAATion clinical program.

The purpose of this first-in human (FIH), double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple-dose Phase 1 study is to assess the safety, tolerability, and pharmacokinetics (PK) of WVE-006 compared to placebo in healthy participants following a single dose (Period 1) and multiple doses (Period 2) of WVE-006.

This information will be used to determine doses and regimes that have the potential to be pharmacologically active in patients with Alpha-1 antitrypsin deficiency in the RestorAATion 2 study, and the maximum safe and tolerable dose that may be given to these patients.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency (AATD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by the Investigator, based on a medical evaluation.
  • Genetic testing confirming PI*MM.
  • Participant has been a non-smoker for at least 1 year prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc).
  • Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections.
  • Any ongoing or recent infections.
  • Any recent or planned vaccinations during the study.
  • Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week.
  • Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits.
  • Participant has a history of caffeine consumption exceeding 8 cups of coffee/day.
  • Use of prescription or non-prescription medications, including vitamin, dietary, and herbal supplements (including St John's Wort) within 7 days prior to the first dose of study treatment unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with interpretation of study assessments. and hormone replacement therapy (HRT) are permitted. If needed, over-the-counter (OTC) medications such as paracetamol/acetaminophen may be used acutely.
  • Any recent or planned major surgery during the study.
  • Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study.
  • Participant has received an agent within 3 months of the Screening Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD): WVE-006 30 milligram (mg) or placebo

    Drug: WVE-006

  • Experimental
    SAD: WVE-006 100 mg or placebo

    Drug: WVE-006

  • Experimental
    SAD WVE-006 200 mg or placebo

    Drug: WVE-006

  • Experimental
    SAD: WVE-006 400 mg or placebo

    Drug: WVE-006

  • Experimental
    SAD: WVE-006 600 mg or placebo

    Drug: WVE-006

  • Experimental
    Multiple Dose: WVE-006 600 mg Every 2 weeks (Q2W) or placebo

    Drug: WVE-006

Interventions

  • DrugWVE-006

    RNA editing oligonucleotide

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants With Adverse Events

    The number of participants who reported an adverse event (AE) will be summarised.

    Time frame: Adverse events are collected from the date of consent until up to 85 days after the dose in Period 1 and up to 113 days after the first dose in Period 2.

Secondary outcomes

  1. Single Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast)

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 1 of the study.

    Time frame: Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.

  2. Single Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax)

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 1 of the study.

    Time frame: Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.

  3. Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 1

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.

    Time frame: Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.

  4. Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 1

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.

    Time frame: Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.

  5. Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 29

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.

    Time frame: Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.

  6. Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 29

    Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.

    Time frame: Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.

07

Results

Posted Mar 23, 2026

Participant flow

Study recruitment was undertaken at one site in the United Kingdom. The recruitment process began in November 2023 and concluded in October 2024. A sufficient number of volunteers were screened in order to successfully recruit 46 completing participants (with one participant withdrawal).

Participant flow — Overall Study
MilestonePeriod 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2W
Started106566662
Completed106566562
Not completed00000100
Withdrew: Withdrawal by subject00000100

Outcome measures

PrimaryThe Proportion of Participants With Adverse Events

The number of participants who reported an adverse event (AE) will be summarised.

Time frame:
Adverse events are collected from the date of consent until up to 85 days after the dose in Period 1 and up to 113 days after the first dose in Period 2.
Reported as:
Count of participants · Participants
The Proportion of Participants With Adverse Events
ParticipantsPeriod 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2W
The Proportion of Participants With Adverse Events85433321
SecondarySingle Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast)

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 1 of the study.

Time frame:
Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.
Reported as:
Mean · h*ng/mL
Single Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast)
h*ng/mLPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mg
Single Ascending Dose (Period 1) - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast)626 ± 1151978 ± 3577507 ± 442729466 ± 1068853342 ± 13166
SecondarySingle Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax)

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 1 of the study.

Time frame:
Samples collected at the following timepoints: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr & 12 hr post-Day 1 dose, Day 2: 24 hr & 36 hr post-Day 1 dose, Day 3: 48 hr post-Day 1 dose, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 & 85.
Reported as:
Mean · ng/mL
Single Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax)
ng/mLPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mg
Single Ascending Dose - Maximum Concentration of WVE-006 in Plasma (Cmax)40.4 ± 11.6112 ± 42.2562 ± 4402038 ± 8643718 ± 963
SecondaryMultiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 1

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.

Time frame:
Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Reported as:
Mean · h*ng/mL
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 1
h*ng/mLPeriod 2 Cohort 1 - WVE-006 600 mg Q2W
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 175678 ± 44053
SecondaryMultiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 1

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.

Time frame:
Samples collected at the following timepoints for Day 1 measurement: Day 1 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Reported as:
Mean · ng/mL
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 1
ng/mLPeriod 2 Cohort 1 - WVE-006 600 mg Q2W
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 15929 ± 4933
SecondaryMultiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 29

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast) of WVE-006 in plasma for participants in Period 2 of the study.

Time frame:
Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Reported as:
Mean · h*ng/mL
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 29
h*ng/mLPeriod 2 Cohort 1 - WVE-006 600 mg Q2W
Multiple Ascending Doses - Area Under the Plasma Concentration Time Curve for WVE-006 From Time of Dosing to the Last Measurable Concentration (AUClast) - Day 2975824 ± 44437
SecondaryMultiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 29

Plasma samples were obtained in order to evaluate defined plasma pharmacokinetic parameters for WVE-006. This endpoint will report the summary of derived pharmacokinetic parameters for the Maximum concentration of WVE-006 in plasma (Cmax) of WVE-006 in plasma for participants in Period 2 of the study.

Time frame:
Samples collected at the following timepoints for Day 29 measurement: Day 29 pre-dose, 30 mins, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr & 24 hr post-dose.
Reported as:
Mean · ng/mL
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 29
ng/mLPeriod 2 Cohort 1 - WVE-006 600 mg Q2W
Multiple Ascending Doses - Maximum Concentration of WVE-006 in Plasma (Cmax) - Day 295995 ± 5419

Adverse events

Collected over Adverse events were reported through ad hoc reporting from the participants from the point of signature of informed consent through to study completion (up to 85 days in Period 1 and up to 113 days in Period 2).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Pooled Placebo0/10 (0%)0/10 (0%)8/10 (80%)
Period 1 Cohort 1 - WVE-006 30 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Period 1 Cohort 2 - WVE-006 100 mg0/5 (0%)0/5 (0%)4/5 (80%)
Period 1 Cohort 3 - WVE-006 200 mg0/6 (0%)0/6 (0%)3/6 (50%)
Period 1 Cohort 4 - WVE-006 400 mg0/6 (0%)0/6 (0%)3/6 (50%)
Period 1 Cohort 5 - WVE-006 600 mg0/6 (0%)0/6 (0%)3/6 (50%)
Period 2 Cohort 1 - WVE-006 600 mg Q2W0/6 (0%)0/6 (0%)2/6 (33.3%)
Period 2 Cohort 1 - Placebo Q2W0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPeriod 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2W
Skin AbrasionSkin and subcutaneous tissue disorders0/100/60/50/60/60/60/61/2
Blood Creatinine Phosphokinase IncreasedInvestigations1/101/62/50/60/61/60/60/2
RashSkin and subcutaneous tissue disorders1/101/62/51/60/60/60/60/2
Transaminases IncreasedInvestigations1/101/62/50/60/60/60/60/2
Influenza like IllnessInfections and infestations1/100/60/50/61/62/62/60/2
NasopharyngitisInfections and infestations2/102/61/50/60/60/60/60/2
HeadacheNervous system disorders2/101/60/50/61/61/61/60/2
ArthralgiaMusculoskeletal and connective tissue disorders1/100/61/50/60/60/61/60/2
ToothacheInjury, poisoning and procedural complications0/100/61/50/60/60/60/60/2
Abdominal DiscomfortGastrointestinal disorders0/101/60/50/60/60/60/60/2

Baseline characteristics

This analysis population included all 47 enrolled participants.

Age, Categorical
Age, Categorical(Participants)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
<=18 years000000000
Between 18 and 65 years10656666247
>=65 years000000000
Age, Continuous
Age, Continuous(Years)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
Mean35.8 ± 9.034.0 ± 8.744.4 ± 11.934.0 ± 10.236.8 ± 9.334.8 ± 8.939.0 ± 12.139.5 ± 7.836.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
Female4404221118
Male6252445129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
Hispanic or Latino001000001
Not Hispanic or Latino10646666246
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
American Indian or Alaska Native000000000
Asian000000011
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000101
White10656664144
More than one race000000101
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(participants)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
United Kingdom10656666247
Weight
Weight(Kilograms)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
Mean77.57 ± 11.6182.38 ± 14.7589.60 ± 8.7865.40 ± 10.8873.95 ± 8.4582.45 ± 9.5974.10 ± 16.6191.20 ± 28.4378.17 ± 12.54
Height
Height(Metres)Period 1: Pooled PlaceboPeriod 1 Cohort 1 - WVE-006 30 mgPeriod 1 Cohort 2 - WVE-006 100 mgPeriod 1 Cohort 3 - WVE-006 200 mgPeriod 1 Cohort 4 - WVE-006 400 mgPeriod 1 Cohort 5 - WVE-006 600 mgPeriod 2 Cohort 1 - WVE-006 600 mg Q2WPeriod 2 Cohort 1 - Placebo Q2WTotal
Mean1.740 ± 0.1031.678 ± 0.1131.792 ± 0.0641.677 ± 0.0781.722 ± 0.0831.742 ± 0.0371.748 ± 0.1001.770 ± 0.1841.725 ± 0.089

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Simbec-Orion Clinical Pharmacology,
    Merthyr Tydfil, Wales CF48 4DR, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Jan 2, 2024
StartActual
Nov 14, 2023
Primary completionActual
Feb 13, 2025
CompletionActual
Feb 13, 2025
Results first posted
Mar 23, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06186492
Lead sponsor
Wave Life Sciences USA, Inc.
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Nov 14, 2023
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Results posted
Mar 23, 2026
Last update
Mar 23, 2026

Study contacts

Cynthia Caracta, MD
study director · Wave Life Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion